FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 168 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR For Early-Stage Cervical Cancer, Minimally Invasive Surgery Declining May 25, 2021 Engaging People with Low-Grade Glioma in Cancer Research August 24, 2023 Reunión anual de la American Society of Clinical Oncology de 2023:... May 25, 2023 2021/22 in review: Charity looks to the future with ambitious new... July 21, 2022 Load more HOT NEWS Accepting Help During Cancer Is Hard, But It Can Benefit You... Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility... EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab 120 years of discovery: 10 ways we’ve changed the story for...
